Clinical · Molecular biology
Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial
Summary
This SUMMIT basket trial study evaluated the efficacy of neratinib alone or in combination with trastuzumab in patients with HER2-mutant metastatic triple-negative breast cancer (TNBC). Results showed confirmed objective response rates of 40% for neratinib alone and 35.3% for the combination, with median progression-free survival times of 2.89 and 6.24 months, respectively. Circulating tumor DNA (ctDNA) monitoring correlated decreases in HER2 mutation variant allele frequencies with treatment response and identified the emergence of resistance mutations. The neratinib and trastuzumab combination appears to prolong responses compared to neratinib alone, offering a novel approach for biomarker-defined metastatic TNBC.
Critical appraisal
Clinical. This phase II study (SUMMIT basket trial) explores a targeted approach for metastatic HER2-mutant triple-negative breast cancer (TNBC), a population with limited treatment options. Confirmed objective response rates (ORR) of 40% for neratinib and 35.3% for the neratinib + trastuzumab combination, along with median progression-free survival (PFS) of 2.89 and 6.24 months respectively, suggest a clinical benefit, particularly with the combination. Although a small study (n=27), these data have already led to the inclusion of neratinib-based combinations in NCCN guidelines for metastatic breast cancer with activating HER2 mutations. This indicates a rapid clinical impact, potentially within 1-3 years, by providing a biomarker-validated therapeutic option for a specific patient subpopulation.
Molecular biology. The discovery of HER2 mutations as a therapeutic target in TNBC is significant, affecting 1-3% of these cancers. The study utilized circulating tumor DNA (ctDNA) sequencing to monitor treatment response and the emergence of resistance mechanisms. The decrease in HER2 mutation variant allele frequencies in ctDNA correlated with clinical response, demonstrating the analytical validity of ctDNA as a dynamic biomarker. The identification of emerging or increasing mutations in ERBB3 (on-pathway) as well as KRAS and TP53 (off-pathway) provides crucial insights into neratinib resistance mechanisms. These biomolecular discoveries pave the way for future clinical tests to identify these resistance mutations and guide sequential or combined therapeutic strategies, potentially via NGS panels on liquid biopsies.
The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology